JPH012551A - Dietary composition and method for producing the same - Google Patents
Dietary composition and method for producing the sameInfo
- Publication number
- JPH012551A JPH012551A JP63-63749A JP6374988A JPH012551A JP H012551 A JPH012551 A JP H012551A JP 6374988 A JP6374988 A JP 6374988A JP H012551 A JPH012551 A JP H012551A
- Authority
- JP
- Japan
- Prior art keywords
- selenium
- algae
- dietary composition
- fatty acids
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000007882 dietary composition Nutrition 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 241000195493 Cryptophyta Species 0.000 claims description 25
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 23
- 229910052711 selenium Inorganic materials 0.000 claims description 23
- 239000011669 selenium Substances 0.000 claims description 23
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 16
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 9
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 9
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000021323 fish oil Nutrition 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- SBHCLVQMTBWHCD-METXMMQOSA-N (2e,4e,6e,8e,10e)-icosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C(O)=O SBHCLVQMTBWHCD-METXMMQOSA-N 0.000 claims 1
- HXWJFEZDFPRLBG-UHFFFAOYSA-N Timnodonic acid Natural products CCCC=CC=CCC=CCC=CCC=CCCCC(O)=O HXWJFEZDFPRLBG-UHFFFAOYSA-N 0.000 claims 1
- -1 amine salt Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940091258 selenium supplement Drugs 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 15
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 15
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 15
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000003026 cod liver oil Substances 0.000 description 6
- 235000012716 cod liver oil Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 235000013310 margarine Nutrition 0.000 description 3
- 239000003264 margarine Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 235000003441 saturated fatty acids Nutrition 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000195628 Chlorophyta Species 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241001125048 Sardina Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 206010039921 Selenium deficiency Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は１食餌性組成物、およびその製造方法に関する
。DETAILED DESCRIPTION OF THE INVENTION Field of the Invention The present invention relates to a dietary composition and a method for its production.
Ｃ１８〜２２：ω−３位不飽和脂肪酸が優れた生物学的
特性を有していることは、知られている。これらの物質
のうち、エイコサペンタエン酸（ＥＰＡ）およびドコサ
ヘキサエン酸（ＤＨＡ）が、主なものである。It is known that C18-22: ω-3 unsaturated fatty acids have excellent biological properties. Among these substances, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the main ones.
ダイヤーパーグ（Ｄｙａｒｂｅｒｇ）等は１両方の酸の
重要性、および多種多様な生物学的効果について述べて
いる（ザ・ランセット（Ｔｈｅ Ｌａｎｃｅｔ）１５，
１１７ページ（１９８７年）参照）。Dyarberg et al. describe the importance of both acids and their wide variety of biological effects (The Lancet 15,
(See page 117 (1987)).
高脂血症および血栓症において、ポリ不飽和脂肪酸、主
として、ＥＰＡおよび口Ｈ＾が果たす重要な役割として
の効果は、グツドナイト（Ｇｏｏｄｎｉ＜ｈｔ）等によ
って報告されている（動脈硬化（Ａｒｔｅｒｉｏｓｃｌ
ｅｒｏｓｉｓ）え、８７ページ（１９８２年）参照）。The effect of polyunsaturated fatty acids, mainly EPA and H^, as important roles in hyperlipidemia and thrombosis has been reported by Goodni et al.
(see p. 87 (1982)).
魚油の有効成分であるＥＰＡおよびＤＨＡは、ＰＧ−３
シリーズの生合成の前駆体であり、また、それらは、ア
ラキドン酸から出発する一連の複雑な生合成過程である
ｒアラキドン酸カスケード」から生ずるＴＸＡ２および
ＴＸＢ、のように有害な代謝中間体の生成を抑制する。EPA and DHA, the active ingredients of fish oil, are PG-3
The production of harmful metabolic intermediates such as TXA2 and TXB, which result from the 'arachidonic acid cascade', which is a series of complex biosynthetic processes starting from arachidonic acid. suppress.
ポリ不飽和脂肪酸には、多くの優れた作用がある一方、
欠点もある。つまり、基の過剰酸化により、最も有害な
マロンジアルデヒドを生じさせるもとになり、それによ
って、中枢神経系に、いわゆる［セロイドーリポフスチ
ノーシス」を発症させることである。While polyunsaturated fatty acids have many excellent effects,
There are also drawbacks. That is, the over-oxidation of the group gives rise to the most harmful malondialdehyde, which leads to the development of so-called ``ceroid-lipofuscinosis'' in the central nervous system.
消化目的のために、ＥＰＡをシクロデキストリン包接化
合物の形で利用する方法が、フランス国特許第２，５５
０，４４５号明細書に開示されている。マーシャル（Ｍ
ａｒｓｃｈａｌｌ）等は、食餌性栄養におけると同じよ
うに、α−リルン酸およびプロスタグランジンの合成に
おけるω−３位ポリ不飽和脂肪酸の役割について報告し
ている（アメリカン・ジャーナル・オブ・クリニカル・
ニュートリオロジー（Ａｍ、、Ｉ。A method of utilizing EPA in the form of a cyclodextrin clathrate for digestive purposes is disclosed in French Patent No. 2,55
No. 0,445. Marshall (M
(American Journal of Clinical
Nutriology (Am,, I.
Ｃ１１ｎ、Ｎｕｔｒ、）３８．８９５ページ（１９８３
年）参照）。C11n, Nutr, ) 38.895 pages (1983
).
魚油は、ＥＰＡおよびＤＨＡのほか、多量の飽和脂肪酸
および低飽和脂肪酸、ならびに非水解性成分を含んでい
る。それを除去することは、血液のトリグリセリド斌、
およびカロリー摂取が、食餌量の増加によって敏感に高
められるので、非常に重要である。In addition to EPA and DHA, fish oil contains large amounts of saturated and less saturated fatty acids and non-hydrolyzable components. It removes blood triglycerides,
and caloric intake are of great importance since they are sensitively increased by increasing food intake.
また１食餌的観点から有害なものであるステロイド類、
例えばコレステロール、ならびに人体に蓄積しやすいビ
タミンＤ（その前駆体）およびビタミンＡも、非水解性
成分の中に含まれている。Also, steroids, which are harmful from a dietary standpoint,
For example, cholesterol, as well as vitamin D (its precursor) and vitamin A, which tend to accumulate in the human body, are also included among the non-hydrolyzable components.
ω−３位ポリ不飽和脂肪酸、ならびに主なＥＰＡおよび
ＤＨＡの食餌的効果は、それらの多くの生理学的な面と
関連して、他の多数の文献に報告がある（例えば、ニー
・バーセルリ（Ｕ、Ｂａｒｃｅｌｌｉ）：スロンボシス
・リサーチ（Ｔｈｒｏｍｂ、Ｒｓｓ、 ）３９．３０７
ページ（１９８５年）；ジェイ・ジェイ・ジュルコフス
キー（Ｊ、Ｊ、Ｊｕｒｋｏｗｓｋｉ）：ＪＮＣＩ ７４
．１１４５ページ（１９８５年）；アー・レンプケ（Ａ
。The dietary effects of ω-3 polyunsaturated fatty acids, and the main EPA and DHA, in relation to their many physiological aspects, have been reported in numerous other publications (e.g. Nie Barcellulli U, Barcelli): Thrombosis Research (Thromb, Rss, ) 39.307
Page (1985); J.J. Jurkowski: JNCI 74
．． 1145 pages (1985); A. Lempke (A.
.
Ｌｅｍｂｋｅ） ：ミルヒヴイツセンシャフト（Ｍｉｌ
ｃｈｖｉｓｓ−・ｅｎｓｃｈａｆｔ）４０．３２９ペー
ジ（１９８５年）を参照）。Lembke): Milchwitzsenschaft (Mil
(1985)).
よく知られているように１人類は、太古から。As is well known, humankind has existed since ancient times.
藻類を栄養源として食している。藻類は、主として、極
東地域で摂取されているが、近年、先進諸国でも、乾燥
状若しくは錠剤にして広く利用されている。They eat algae as a source of nutrition. Algae are mainly ingested in the Far East, but in recent years they have been widely used in developed countries as well, either in dried form or in the form of tablets.
藻類は、非常に有用な栄養物を有している。その理由は
、乾燥状の藻類が、健康な生命維持に不可欠な物質、例
えば、ビタミン、蛋白質、微量元素を有する複合蛋白質
、糖類、ポリ不飽和脂肪酸などを、高い濃度で含んでい
るからである。Algae contain very useful nutrients. This is because dry algae contains high concentrations of substances essential for healthy life, such as vitamins, proteins, complex proteins with trace elements, sugars, and polyunsaturated fatty acids. .
藻類に関する詳しいことは、例えば、ゼイジック（Ｚａ
ｊｉｃ）による著書、「藻類の性質および生成物（Ｐｒ
ｏｐｅｒｔｉｅｓ ａｎｄ ｐｒｏｄｕｃｔＳｏｆ ａ
ｌｇａｅ）Ｊ（米国ニューヨーク、ブラナム（Ｐｌａｎ
ｕｍ）出版、 （１９７０年））に紹介されている。For more information about algae, see, for example, Zaysik (Za
``Properties and Products of Algae (Pr.
operties and productsSof a
lgae) J (Plan, New York, USA)
um) Publishing, (1970)).
微量元素の生物学的効果に関する研究は、始まってから
まだ１０年位である。それにより、セレンは、生命維持
に大変重要かつ不可欠の物質の一つであることが分かっ
てきた。セレンの有利な作用は、主として、グルタチオ
ンペルオキシダーゼの活性発現性にあり、より詳しくい
うと、有害な過剰酸化過程の最も重要な内在抑制因子で
ある酵素の補欠分子族の活性化にある。Research on the biological effects of trace elements has only been underway for about 10 years. As a result, selenium has been found to be one of the very important and essential substances for sustaining life. The beneficial action of selenium lies primarily in the activation of glutathione peroxidase, and more particularly in the activation of the prosthetic group of the enzyme, which is the most important endogenous inhibitor of harmful hyperoxidative processes.
セレンは１体内に蓄積されないため、絶えず補充されな
ければらない、従来、セレンは、主として、二酸化セレ
ンおよび亜セレン酸ナトリウムのように、無機化合物の
形で供給されてきた。Selenium is not stored in the body and must be constantly replenished. Traditionally, selenium has been supplied primarily in the form of inorganic compounds, such as selenium dioxide and sodium selenite.
セレンは、それ自体で、血圧降下作用を有し、かつ心臓
の阻血状態、低酸素状態、および梗塞状態を好転させ、
また、中枢神経系のセロイドーリポフスチノーシスを抑
制する。更に、セレンは、歯根膜炎にも優れた効果を発
揮するとともに、ガン疾患の発現を抑制することも実証
されている。Selenium itself has a hypotensive effect and improves cardiac ischemia, hypoxia, and infarction,
It also suppresses ceroid lipofuscinosis in the central nervous system. Furthermore, it has been demonstrated that selenium exhibits an excellent effect on periodontitis and suppresses the development of cancer diseases.
また、セレンは、抗発ガン性剤であると見做されている
。Selenium is also considered to be an anti-carcinogenic agent.
多くの変調若しくは疾患、例えば、肝ｉｌ壊死、筋壊死
、赤血球膜の破壊、間質性病変、心電図（ＥＣＧ）にお
けるＳＴ高位状態、クワジオルコル症候群（蛋白質栄養
障害）、および多発性硬化症は、それぞれ、セレン欠乏
によって起こることが実証されている。Many modulations or diseases, such as hepatic il necrosis, myonecrosis, destruction of red blood cell membranes, interstitial lesions, ST-high status on the electrocardiogram (ECG), Kwaziorkor syndrome (protein malnutrition disorder), and multiple sclerosis, respectively , has been demonstrated to be caused by selenium deficiency.
セレンの生物学的効果に関する評論として発行されてい
るものに、スレッサ（Ｔｈｒｅｓｓａ）等にュートリシ
ョン・レビュー（Ｎｕｔｒｉｔｉｏｎ Ｒｅｖｉｅｗ）
３５．７ページ（１９７７年））によるもの、アール・
アイ・シャンバーガー（Ｒ，１，Ｓｈａｍｂｅｒｇｅｒ
） （ジャーナル・オブ・エンバイロメンタル・パソロ
ジー・アンド・トキシコロジー（Ｊ、ｏｆ Ｅｎｖ、Ｐ
ａｔｈ＝ａｎｄ Ｔｏｘ、）４，３０５ページ（１９８
０年））によるもの、およびマスカワ（Ｍａｓｕｋａｖ
ａ）等（エクスペリエンチア（ｌＥｘｐｅｒｉｅｎｔｉ
ａ）３９．４０５ページ（１９８３年））によるものが
ある、′すなわち１本発明の目的は、不飽和脂肪酸の摂
取に係る不利な生物学的効果を排除し、ＥＰＡ、 ＤＨ
Ａ。Among the reviews published on the biological effects of selenium, Nutrition Review by Thressa et al.
35.7 pages (1977)), by R.
I Shamberger (R, 1, Shamberger)
) (Journal of Environmental Pathology and Toxicology (J, of Env, P
ath=and Tox,) 4,305 pages (198
0 years)) and Masukav
a) etc. (lExperienti
a) p. 39.405 (1983)), i.e. 1. The object of the present invention is to eliminate the adverse biological effects associated with the intake of unsaturated fatty acids and to improve the effectiveness of EPA, DH
A.
藻類およびセレンの優れた特性の組合わせを与え、かつ
組成をベースに、不健康な生命管理の少なくとも一部、
および栄養の悪い食性に均衡を酷らせうる食餌性組成物
を開発することである。At least some of the unhealthy life management, based on the composition, giving a combination of excellent properties of algae and selenium,
and to develop dietary compositions that can overwhelm the nutritional imbalance.
（発明の要約）
本発明は、セレン含有藻類、およびポリ不飽和脂肪酸を
含む食餌組成物により、上記の目的は完全に達成される
という認識に基づいている。SUMMARY OF THE INVENTION The present invention is based on the recognition that the above objects are fully achieved by dietary compositions comprising selenium-containing algae and polyunsaturated fatty acids.
本発明は、０．５〜５０重量％のセレン含有藻類と、少
なくとも２つの二重結合を有する９９．５〜５０重量％
のＣ１８〜２２不飽和脂肪酸若しくはその誘導体と。The present invention comprises 0.5-50% by weight of selenium-containing algae and 99.5-50% by weight having at least two double bonds.
C18-22 unsaturated fatty acids or derivatives thereof.
食品工業で通常使用の添加剤と１選択的使用の酸化防止
剤とを含む食餌性組成物に関するものである。The present invention relates to dietary compositions containing additives commonly used in the food industry and optionally antioxidants.
また、本発明は、０．５〜５０重量％のセレン含有藻類
と、少なくとも２つの二重結合を有する９９．５〜５０
重量％のＣ１８〜２２不飽和脂肪酸若しくはその誘導体
と１食品工業で通常使用される添加剤と１選択的使用の
酸化防止剤とを含む上記食餌性組成物の製造方法に関す
るものである。The present invention also provides selenium-containing algae containing 0.5 to 50% by weight and 99.5 to 50% by weight having at least two double bonds.
The present invention relates to a method for producing the aforementioned dietary composition comprising % by weight of C18-22 unsaturated fatty acids or derivatives thereof, one additive commonly used in the food industry, and one selectively used antioxidant.
セレン含有藻類は１本出願人により日本国に同時出願さ
れた明細書（対応ハンガリー国特許願第５７５７８８号
明細書）に記載の要領で、調製される。The selenium-containing algae is prepared as described in the specification (corresponding Hungarian Patent Application No. 575,788) co-filed in Japan by the same applicant.
組成物の有効成分として用いられるＣ１１〜２２：ω−
３位不飽和脂肪酸の原料は、種々の海水魚および淡水魚
、主として、さば、鱈、鯉、鰯、およびいかから得られ
る油、ならびに例えば鱈肝油および鮫肝油のようにこれ
らの魚の肝臓から得られる油である。C11-22 used as an active ingredient of the composition: ω-
Sources of tertiary unsaturated fatty acids are oils obtained from various marine and freshwater fish, primarily mackerel, cod, carp, sardine, and squid, and from the livers of these fish, such as cod liver oil and shark liver oil. It's oil.
藻類として、クロレラまたは緑藻（Ｓｃａｎａｄｅｓ■
ＵＳ）を主に使用する。それらは１人間の栄養物として
利用でき、かつ優れた生物学的作用を有している。As algae, chlorella or green algae (Scanades)
US) is mainly used. They can be used as human nutrition and have excellent biological effects.
本組成物は、酸化され易い、従って、活性防腐剤、例え
ば、α−トコフェロール（ビタミンＥ）、グルタチオン
、またはブチルヒドロキシトルエンのような伝統的酸化
防止剤を用いるのが好ましい。The composition is susceptible to oxidation, therefore it is preferred to use active preservatives, such as traditional antioxidants such as alpha-tocopherol (vitamin E), glutathione, or butylated hydroxytoluene.
均質化した組成物を、栄養物、錠剤、カプセルなどに含
ませることができる。ここでいう「栄養物」なる用語は
、経口的若しくは非経口的投与により用いられるすべて
のものを意味する。経口投与物は、菓子類（例えば、チ
ョコレート、ケーキ）、食肉類、香辛料、マーガリン、
ミルク、バター類、油類などを含む。The homogenized composition can be included in nutritional products, tablets, capsules, and the like. The term "nutrition" as used herein means anything that is administered orally or parenterally. Orally administered products include confectionery (e.g. chocolate, cake), meat, spices, margarine,
Contains milk, butter, oils, etc.
本発明による主な利点は、次のように要約できる。The main advantages of the invention can be summarized as follows.
（ａ）組成物中の個々の成分は、それ自体で、重要な生
物学的および栄養的効果があり、かつＥＰＡ。(a) The individual ingredients in the composition have important biological and nutritional effects on their own and the EPA.
ＤＨＡ、セレン、および藻類の優れた特性がうまく組み
合わされている。It combines the best properties of DHA, selenium, and algae.
（ｂ）ポリ不飽和脂肪酸の摂取の際に現われるセロイド
ーリボフスチノーシスの可能性は、排除される。(b) The possibility of ceroid-ribofuscinosis, which appears upon the intake of polyunsaturated fatty acids, is excluded.
（Ｃ）本発明による組成物は、上で述べた有害な魚油成
分（飽和脂肪酸、コレステロール、ビタミンＡおよびＤ
）を含んでいないため、本組成物の摂取による連続規定
食餌法を使う必要がない。(C) The composition according to the invention contains the harmful fish oil components mentioned above (saturated fatty acids, cholesterol, vitamins A and D).
), there is no need to use a continuous diet method by ingesting this composition.
（ｄ）セレンが、藻類に濃縮された自然の形で、つまり
天然の材料として入っている。(d) Selenium is present in concentrated natural form in algae, that is, as a natural material.
（ｅ）本組成物は、心臓血管系の卒中状態および血栓塞
栓状態の予防、つまり、梗塞および卒中の発症抑制、な
らびにアトピー性疾患の予防に有用である０発症状態に
おいて、本組成物を使用することが特に好適である。(e) The composition is useful in the prevention of stroke and thromboembolic conditions of the cardiovascular system, that is, the inhibition of the onset of infarction and stroke, and the prevention of atopic diseases. It is particularly preferred to do so.
以下、好適実施例により、本発明の詳細な説明する、た
だし、本発明は、これらの実施例に制約されるものでは
ない。Hereinafter, the present invention will be described in detail with reference to preferred embodiments, but the present invention is not limited to these embodiments.
基礎的材料として使用される成分の調製法を、実施例１
．２および３で説明し１本組成物の調製法は、それ以外
の実施例で説明する。Example 1 shows how to prepare the components used as basic materials.
．． The method for preparing the composition described in Sections 2 and 3 will be explained in other Examples.
夫旌魅よ
１０ｋｇの鰯油を、５０〜６０℃の温度で、９５％エタ
ノール１０ｎ中２）ｃｇの水酸化ナトリウムを含有する
溶液に加えた。その混合液を、窒素存在下で２時間還流
した後、攪拌しながら、 １０℃に冷却した。飽和脂肪
酸の沈殿結晶ナトリウム塩を濾過し、少量のエタノール
で洗浄した。エタノール炉液の蒸発を行ない、その残分
に、２０Ｑの沸騰水を加えた。10 kg of sardine oil were added to a solution containing 2) cg of sodium hydroxide in 10 n of 95% ethanol at a temperature of 50-60°C. The mixture was refluxed for 2 hours under nitrogen and then cooled to 10° C. with stirring. The precipitated crystalline sodium salts of saturated fatty acids were filtered and washed with a small amount of ethanol. The ethanol furnace liquid was evaporated, and 20Q of boiling water was added to the residue.
コレステロールのような非水解性化合物を、５Ｑのヘキ
サンによる抽出により除去した。抽出水相に希硫酸を加
えて、ＰＨ２とし、１５ｆｌのヘキサンを用いて、再び
それの抽出を行なった。Non-hydrolyzable compounds such as cholesterol were removed by extraction with 5Q hexane. Dilute sulfuric acid was added to the extracted aqueous phase to adjust the pH to 2, and it was extracted again using 15 fl of hexane.
有機相を水で洗浄し、無水硫酸ナトリウムを用い脱水し
てから、蒸発を行なった結果、ＤＨ＾含量３６．８％、
およびＥＰＡ含量３１．８％の油状濃縮物３．２瞳を得
た。この油状物は、褐色を呈し、かつ魚臭がした。そこ
で、この油状濃縮物に酸性白土を混ぜ合わせ１次に、そ
れを、窒素の存在下で、１０５℃にて１０分間加熱し、
熱い状態で濾過した。温度１７０℃、１．３バールの減
圧下で、３時間蒸気蒸留を行ない、脱臭した結果、組成
物に変化を起こさせず、淡黄色、無味無臭の油１．６ｋ
ｇが得られた。The organic phase was washed with water, dehydrated using anhydrous sodium sulfate, and then evaporated, resulting in a DH content of 36.8%.
and an oily concentrate 3.2 pupil with an EPA content of 31.8% was obtained. This oil was brown in color and had a fishy odor. Therefore, this oily concentrate was mixed with acid clay, and then heated at 105°C for 10 minutes in the presence of nitrogen.
Filter hot. Steam distillation was carried out for 3 hours at a temperature of 170° C. and under a reduced pressure of 1.3 bar to deodorize the oil, resulting in a pale yellow, tasteless and odorless oil of 1.6 kg with no change in composition.
g was obtained.
失胤涯１
２４ｋｇの鰐肝油を、６０℃にて１６Ｑのメタノールに
溶解し、この溶液に対して、４０％水酸化ナトリウム溶
液８ｋｇを、５０〜６０℃の温度範囲で攪拌しながら消
却した。混合液を、６０℃にて更に４５分間攪拌した０
次に、′＃Ｊ６０℃のその溶液に対して、１５％塩酸２
０ｋｇを加えた。Loss of Seed 1 24 kg of crocodile liver oil was dissolved in 16Q methanol at 60°C, and 8 kg of 40% sodium hydroxide solution was quenched with stirring at a temperature range of 50-60°C. The mixture was stirred for an additional 45 minutes at 60°C.
Next, add 15% hydrochloric acid 2 to the solution at 60°C.
Added 0 kg.
相を分離させた後、１５％塩酸１０ｋｇを用いて、有機
相の抽出を行ない１次に、熱い水道水約１８０１１を用
いて、中性になるまで洗浄した。相を分離させてから、
油相に対して１００Ωのアセトンを加えた。混合液を約
４５℃に加熱してから、水３０Ｑ中３．８−の水酸化リ
チウムモノヒトラード含有溶液を加えた。３０分間攪拌
した後、混合物を一晩放置した。After phase separation, the organic phase was extracted with 10 kg of 15% hydrochloric acid and washed with approximately 18,011 g of hot tap water until neutral. After separating the phases,
100Ω of acetone was added to the oil phase. The mixture was heated to about 45° C. before a solution containing 3.8-lithium hydroxide monohydroxide in 30Q water was added. After stirring for 30 minutes, the mixture was left overnight.
それを濾過し、アセトン炉液の蒸発を行なった。It was filtered and the acetone solution was evaporated.
残分に、１５％塩酸８ｋｇを加えて酸性とし、ヘキサン
を用いて３回抽出を行なってから、蒸発させた。The residue was made acidic by adding 8 kg of 15% hydrochloric acid, extracted three times with hexane, and then evaporated.
精製のためのすべての操作は、窒素存在下で行なった。All purification operations were performed under nitrogen.
このようにして、ヨウ素価２５８．および酸価１６０の
精製魚油６．４ｋｇが得られた。In this way, the iodine value is 258. 6.4 kg of purified fish oil with an acid value of 160 was obtained.
このようにして精製された鱈肝油１ｋｇを、６０℃にて
、メタノール９ａ中３ｋｇの尿素含有溶液に消却した。1 kg of cod liver oil purified in this way was quenched at 60° C. in a solution containing 3 kg of urea in methanol 9a.
混合液を同じ温度で２時間攪拌した後。After stirring the mixture at the same temperature for 2 hours.
冷却してから、−１８℃に設定された冷蔵庫の中で一晩
放置した。それを濾過し、炉液の蒸発を行なった。残分
に、２．５２の塩酸（酢と水との稀釈率１：１）を加え
、その混合物を１５分間攪拌した。After cooling, it was left overnight in a refrigerator set at -18°C. It was filtered and the filtrate was evaporated. To the residue, 2.52 parts of hydrochloric acid (1:1 dilution ratio of vinegar and water) was added and the mixture was stirred for 15 minutes.
ヘキサンによる抽出後、その有機相を、中性になるまで
水で洗浄し１次に、無水硫酸ナトリウムを用いて脱水し
た後、蒸発を行なった結果、ヨウ素価３１５． ＥＰＡ
含［２４％、およびＤＩ＾含量４２％のω−３位脂肪酸
０．３４ｋｇが得られた。After extraction with hexane, the organic phase was washed with water until neutral, first dehydrated using anhydrous sodium sulfate, and then evaporated. As a result, the iodine value was 315. EPA
0.34 kg of omega-3 fatty acids containing 24% and DI^ content of 42% was obtained.
１直旌１
８Ｑのクノップープリングスハイム（Ｋｎｏｐ−Ｐｒｉ
ｎｇｓｈｅｉｓ）培養基を、１０ρ容の藻類培養ガラス
ビンに入れ、それに、４０■の亜セレン酸ナトリウムを
加えた。装置系を、１バールの過圧下で。1 straight 1 8Q Knop-Pri
ngsheis) culture medium was placed in a 10 μ volume algae culture glass bottle, to which 40 μ of sodium selenite was added. Equipment system under 1 bar overpressure.
１２１℃にて３０分間殺菌した。滅菌溶液に、セレン耐
性緑藻の純粋培養藻類を接種した。It was sterilized at 121°C for 30 minutes. The sterile solution was inoculated with a pure culture of selenium-tolerant green algae.
波長が４４０〜５２０乃至６４０〜７００ ｔｔ ｖａ
、照度が４０００ルクスの明るさの放電管により照明し
ながら、５容量％の二酸化炭素を含む滅菌空気を、２５
℃にて培養基に通じて発泡させた。 １４日間の培養後
、培養基から藻類を分離した。Wavelength is 440-520 to 640-700 tt va
Sterilized air containing 5% by volume of carbon dioxide was supplied at 25% by volume while being illuminated by a discharge tube with an illuminance of 4000 lux.
Foam was allowed to pass through the culture medium at °C. After 14 days of culture, algae were separated from the culture medium.
このようにして得られた藻類の塊りを、超音波により分
解し、かつ、温度を６５℃以下にして、注意深く乾燥さ
せた結果、セレン含量１２００μｇ／ｇの粉末藻類６ｇ
が得られた。The algae mass thus obtained was decomposed by ultrasonic waves and carefully dried at a temperature below 65°C. As a result, 6 g of powdered algae with a selenium content of 1200 μg/g was obtained.
was gotten.
失胤旌土
１００ｇのセレン含有藻類（粉末藻類のセレン濃度２６
０μｇ／ｇ）を、６５％濃縮鱈肝油（ＥＰＡ含量２２％
、ＤＨＡ４３％）１５０ｇに混ぜた。均質化後、混合物
に、０．２１轄凌％のビタミンＥを加えて保存した。100g of selenium-containing algae (selenium concentration of powdered algae: 26
0 μg/g) and 65% concentrated cod liver oil (EPA content 22%).
, DHA43%). After homogenization, the mixture was preserved with the addition of 0.21% vitamin E.
スＪ１剛ｊ
食餌性マーガリン組成物の調製
６５％鱈肝油（ＥＰＡ含斌２２％、ＤＨＡ含ｆｔ４３％
）８ｇ。Preparation of dietary margarine composition 65% cod liver oil (22% EPA, 43% DHA)
) 8g.
、 およびセレン含有藻類（粉末藻類中のセレン濃
度２６０μｇ／ｇ） １ ｇを、ソフトマーガリン２５
０ｇに混合し、次に、その混合物を均質化させた。, and 1 g of selenium-containing algae (selenium concentration in powdered algae 260 μg/g) was mixed with 25 g of soft margarine.
0g and then the mixture was homogenized.
実施例６
出発材料を、次の量で使用した以外、実施例４に記載の
要領に準じて行なった。Example 6 The procedures described in Example 4 were followed except that the following amounts of starting materials were used.
６２％濃縮鱈肝油（ＥＰＡ含量２２％、ＤＨＡ含量４３
％）を４００ｇゆ
１２００μｇ／ｇのセレンを含有する粉末藻類を７０．
６ｇ。62% concentrated cod liver oil (EPA content 22%, DHA content 43%)
%) and 400g of powdered algae containing 1200μg/g of selenium.
6g.
ビタミンＥを０．４ｇ。0.4g of vitamin E.
このようにして得られた均質化物を、５００■容量の軟
ゼラチンカプセルまたは軟ゼラチンビードカプセルに充
填し、それから、ブリースターフォイルで包装した。The homogenate thus obtained was filled into 500 μ capacity soft gelatin capsules or soft gelatin bead capsules and then packaged in blister foil.
尖嵐貫ユ
従来の製薬機械および方法により、次のような組成を有
する錠剤を調製した。Tablets with the following composition were prepared using conventional pharmaceutical machinery and methods.
ＥＰＡおよびＤＨＡが濃縮され、かつ
防腐剤として０．１％のビタミンＥ
を含んでいる鱈肝油 ２００■（ＤＨ
Ａ含ｆｆ１４３％、ＥＰＡ含量２２％）ラクトース
１４０■澱粉
６０ｗ。Cod Liver Oil 200■ (DH
A content: 143%, EPA content: 22%) Lactose
140 ■ Starch
60w.
ポリビニルピロリドン ３．５■ス
テアリン酸マグネシウム ３．５ｗ：必要
に応じ、バンニング（Ｐａｎｎｉｎｇ）機械を使って１
錠剤を砂糖で被覆する。Polyvinylpyrrolidone 3.5■ Magnesium stearate 3.5w: If necessary, use a panning machine to
Coat the tablets with sugar.
Claims (5)
とも２つの二重結合を有する９９．５〜５０重量％のＣ
＿１＿８＿〜＿２＿２不飽和脂肪酸若しくはその誘導体
と、食品工業で通常使用の添加剤と、選択使用の酸化防
止剤とを含む食餌性組成物。(1) 0.5-50% by weight of selenium-containing algae and 99.5-50% by weight of C having at least two double bonds
_1_8_-_2_2 Dietary compositions comprising unsaturated fatty acids or derivatives thereof, additives commonly used in the food industry, and selectively used antioxidants.
、またはアミン塩を含む請求項（１）記載の食餌性組成
物。(2) The dietary composition according to claim (1), which contains an ester, an alkaline earth salt, or an amine salt as the fatty acid derivative.
−エイコサペンタエン酸、および４，７，１０，１３，
１６，１９−ドコサヘキサエン酸を含む請求項（１）ま
たは（２）記載の食餌性組成物。(3) As unsaturated fatty acids, 5, 8, 11, 14, 17
-eicosapentaenoic acid, and 4,7,10,13,
The dietary composition according to claim (1) or (2), comprising 16,19-docosahexaenoic acid.
酸を含む請求項（１）記載の食餌性組成物。(4) The dietary composition according to claim (1), which contains a fatty acid obtained from marine fish oil as the unsaturated fatty acid.
とも２つの二重結合を有する９９．５〜５０重量％のＣ
＿１＿８＿〜＿２＿２不飽和脂肪酸若しくはその誘導体
と、食品工業で通常使用の添加剤とを混合し、更に、酸
化防止剤を選択的に混合する段階からなる請求項（１）
記載の食餌性組成物の製造方法。(5) 0.5-50% by weight of selenium-containing algae and 99.5-50% by weight of C having at least two double bonds
Claim (1) comprising the step of mixing an unsaturated fatty acid or a derivative thereof with an additive commonly used in the food industry, and further selectively mixing an antioxidant.
A method of manufacturing the described dietary composition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU871174A HU202088B (en) | 1987-03-18 | 1987-03-18 | Method for producing dietetic preparation |
| HU2251-1174/87 | 1987-03-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH012551A true JPH012551A (en) | 1989-01-06 |
| JPS642551A JPS642551A (en) | 1989-01-06 |
Family
ID=10953177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63063749A Pending JPS642551A (en) | 1987-03-18 | 1988-03-18 | Dietary composition and its production |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPS642551A (en) |
| BE (1) | BE1002429A3 (en) |
| CH (1) | CH677863A5 (en) |
| DD (1) | DD273974A5 (en) |
| DE (1) | DE3809238A1 (en) |
| ES (1) | ES2009248A6 (en) |
| FI (1) | FI881308A (en) |
| FR (1) | FR2612373B1 (en) |
| GB (1) | GB2203043A (en) |
| HU (1) | HU202088B (en) |
| IT (1) | IT1216139B (en) |
| LU (1) | LU87170A1 (en) |
| NL (1) | NL8800691A (en) |
| SE (1) | SE468785B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU210122B (en) * | 1988-03-23 | 1995-02-28 | Biorex Kutato Fejlesztoe Kft | Process for production of composition against thromboembolytic conditions of circulating system and heart |
| GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| DK162621C (en) * | 1989-04-27 | 1992-04-13 | Jon Katborg | FOOD FAT PRODUCT AND PROCEDURE FOR PRODUCING THE SAME |
| JP2525236Y2 (en) * | 1989-09-27 | 1997-02-05 | 株式会社アテックス | Handle position adjustment device for walking type mobile agricultural machine |
| JPH05505935A (en) * | 1990-02-05 | 1993-09-02 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Extended release formulation of vitamins, minerals and other beneficial supplements |
| DE19629433A1 (en) * | 1996-07-22 | 1998-01-29 | Hoechst Ag | Preparation containing omega-3 fatty acids from microorganisms as a prophylactic or therapeutic agent against parasitic diseases in animals |
| GB2363331B (en) * | 2000-06-17 | 2003-02-05 | Raymond Clifford Noble | Supplement to enhance fertility |
| US7416752B2 (en) * | 2004-01-06 | 2008-08-26 | Sharp Ingrained Functional Foods, Inc. | Method of fortifying seeds with an essential fatty acid, fortified seed and food product |
| DE102006021478A1 (en) * | 2006-05-09 | 2007-11-15 | Tilco Biochemie Gmbh | Preparation for body treatment |
| DE102017130419A1 (en) | 2017-07-05 | 2019-01-10 | Richard Kuntzsch | Dietary supplement based on chocolate |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1057844A (en) * | 1951-06-14 | 1954-03-11 | Process for obtaining products intended to remedy food? Ences in trace elements | |
| JPS5545303A (en) * | 1978-09-25 | 1980-03-31 | Yoshio Tanaka | Preparation of health food and its device |
| FR2479657A1 (en) * | 1980-04-03 | 1981-10-09 | Le Trividic Noemie | Prepn. of algae fish sauce from dried pieces - by soaking in aq. white wine, cooking, and mixing with cooking juice contg. algae powder |
| GB2098065A (en) * | 1981-04-14 | 1982-11-17 | Nippon Suisan Kaisha Ltd | Antithrombotic compositions containing docosahexaenoic acid |
| GB2140806B (en) * | 1983-05-28 | 1987-10-28 | Sekimoto Hiroshi | Stabilisation of unsaturated fatty acids, fish oils or fish |
| DE3421644A1 (en) * | 1984-06-09 | 1985-12-12 | Richard 7880 Bad Säckingen Hau | DIET DIAGRAM |
| FR2569536A1 (en) * | 1984-08-30 | 1986-03-07 | Michel Maillols | Biological nutrients |
-
1987
- 1987-03-18 HU HU871174A patent/HU202088B/en not_active IP Right Cessation
-
1988
- 1988-03-17 CH CH1008/88A patent/CH677863A5/de not_active IP Right Cessation
- 1988-03-18 FR FR888803514A patent/FR2612373B1/en not_active Expired - Fee Related
- 1988-03-18 LU LU87170A patent/LU87170A1/en unknown
- 1988-03-18 DE DE3809238A patent/DE3809238A1/en not_active Withdrawn
- 1988-03-18 DD DD88313813A patent/DD273974A5/en not_active IP Right Cessation
- 1988-03-18 ES ES8800826A patent/ES2009248A6/en not_active Expired
- 1988-03-18 FI FI881308A patent/FI881308A/en not_active Application Discontinuation
- 1988-03-18 SE SE8800989A patent/SE468785B/en not_active Application Discontinuation
- 1988-03-18 NL NL8800691A patent/NL8800691A/en not_active Application Discontinuation
- 1988-03-18 IT IT8819835A patent/IT1216139B/en active
- 1988-03-18 GB GB08806531A patent/GB2203043A/en not_active Withdrawn
- 1988-03-18 JP JP63063749A patent/JPS642551A/en active Pending
- 1988-03-18 BE BE8800308A patent/BE1002429A3/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU716372B2 (en) | Food composition containing an omega-6/omega-3 unsaturated fatty acid balance modifier | |
| US7179491B1 (en) | Process of converting rendered triglyceride oil from marine sources into bland, stable oil | |
| EP0770385A1 (en) | Use of astaxanthin for the treatment of stress | |
| JP5934483B2 (en) | Phospholipid-binding DHA increasing agent | |
| JP2021508343A (en) | Lysophosphatidylcholine composition | |
| JP5997887B2 (en) | Oral administration | |
| JPH10155459A (en) | Astaxanthin-containing drink | |
| JPS6158536A (en) | Nutrient composition | |
| JPH09194362A (en) | Composition consisting of phospholipid containing docosahexanenoic acid and eicosapentanenoic acid | |
| JPH012551A (en) | Dietary composition and method for producing the same | |
| AU2019200757A1 (en) | Lipid extraction processes | |
| EP0437520B1 (en) | Triglyceride and nutritional composition comprising such triglyceride | |
| SE468785B (en) | DIETIC COMPOSITION CONTAINING SELENAL ALGUES AND UNSATURED FAT ACIDS, AND PROCEDURES FOR PREPARING THEREOF | |
| JP2006306866A (en) | Adiponectin-increasing agent | |
| JP2002226368A (en) | Inhibitor against oxidative damage to erythrocyte | |
| JP2009269865A (en) | Oral administration agent | |
| AU610141B2 (en) | Pharmaceutical compositions acting on the heart and cardiovascular system and process for preparing same | |
| JPH03297364A (en) | Powdery composition for preventing thrombosis | |
| JP2002159279A (en) | Improving agent with ability to utilize oxygen | |
| JP2009269864A (en) | Agent for increasing phospholipid-bound arachidonic acid | |
| JP6824506B2 (en) | Lipid composition | |
| JP4594489B2 (en) | Specific cancer killing agent and composition comprising the same | |
| JP2005179264A (en) | Body weight gain inhibitor | |
| JP6755530B2 (en) | Pharmaceutical composition for the prevention or treatment of dermatitis | |
| JP2000281572A (en) | Cancericidal agent and composition formulated therewith |